Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
β-catenin transcriptional complex inhibitors
- Development stage
- Preclinical
- Lead developer
- StemSynergy Therapeutics
- Modality
- Small Molecules
01
Overview
β-catenin transcriptional complex inhibitors are a class of small molecule therapeutics being developed by StemSynergy Therapeutics to treat Wnt-driven cancers. These inhibitors work by disrupting the formation or activity of the β-catenin transcriptional complex, which is a key downstream effector of the Wnt signaling pathway. In many cancers, aberrant activation of the Wnt pathway leads to the accumulation of β-catenin in the nucleus, where it binds to TCF/LEF transcription factors to drive the expression of oncogenes. By blocking this transcriptional complex, these agents aim to inhibit tumor growth and progression. The program is currently in the preclinical stage of development.
- Other names
- β-Catenin transcriptional complex inhibitors program
02
Targets
TCF7
Beyond the preview
Go deeper on β-catenin transcriptional complex inhibitors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on β-catenin transcriptional complex inhibitors.